Our study based on the SEER-Medicare linked data, a large population-based national database, revealed that HCC patients with pre-existing T2DM treated with SGLT2 inhibitors had better prognosis relative to patients who were not on SGLT2 inhibitors, especially for those who used SGLT2 inhibitors ≥ 12 months. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.